ARPA-H's Advocate program teams met with FDA within 2 months of launch, aiming to submit autonomous AI heart failure devices ...
Third Rock Ventures strikes up to $2.16B antibody discovery deal with Funnel Biosciences, a little-known Chinese AI biotech.
Boehringer Ingelheim plans 2027 approval for obesity drug survodutide after trial showed no increased CV risk vs placebo; ...
Companies that committed to President Donald Trump’s drug pricing policy now face difficult decisions when launching new ...
Zura Bio shares drop ~70% after bispecific tibulizumab fails Ph2 in hidradenitis suppurativa; company drops the drug in HS.
Marea Therapeutics' investigational lipid-lowering medicine has shown further promise in cutting triglycerides in patients ...
Lilly’s obesity pill Foundayo cut sleep apnea events by up to 43.8% in Phase 3; Lilly plans to file with the FDA by year-end.
Delix Therapeutics has raised $100 million in a Series C to catch up to a budding crop of psychedelics and neuroplastogen ...
Pentagon drops WuXi AppTec from its Chinese military companies list after a court injunction, but leaves the door open to relisting.
Vir Biotechnology's tobevibart/elebsiran combo met primary endpoints in ECLIPSE 1, with 44% achieving undetectable hepatitis ...
Endpoints’ Drew Armstrong and Max Bayer join policy expert Nick Shipley live Wednesday to break down what the US midterms ...
Emily Chaddock survived severe preeclampsia at 27 weeks; daughter Mia born under 2 lbs. No drugs exist to prevent it. Eli ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results